Menu Search
Equities

Codexis Inc

CDXS:NSQ

Codexis Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.08
  • Today's Change-0.10 / -2.39%
  • Shares traded452.00k
  • 1 Year change+150.31%
  • Beta2.1084
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Codexis Inc's revenues fell -49.39% from 138.59m to 70.14m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 33.59m to a larger loss of 76.24m.
Gross margin75.96%
Net profit margin-96.35%
Operating margin-78.97%
Return on assets-41.03%
Return on equity-75.31%
Return on investment-54.21%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Codexis Inc fell by 49.33m. Cash Flow from Financing totalled 8.17m or 11.64% of revenues. In addition the company used 52.64m for operations while cash used for investing totalled 4.86m.
Cash flow per share-0.8111
Price/Cash flow per share--
Book value per share0.902
Tangible book value per share0.8717
More ▼

Balance sheet in USDView more

Codexis Inc appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio3.21
Quick ratio3.15
Total debt/total equity0.3901
Total debt/total capital0.2806
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.